TAGGED IN

Patents

    Samsung Faces Big Penalty for Violating Key Unlocking Patents

    In case it wasn’t obvious, not all the features you find on your Samsung phone are made or invented 100% by Samsung. Like with many companies, Samsung licenses various patents to create its products. Unfortunately, it looks like Samsung might have violated some of them. A US court has ruled that Samsung has infringed upon smart home and smartphone patents and is now required to pay $117.7 million in damages to Japanese company, Maxwell. Samsung to pay for violating patents The lawsuit dates back to 2023. Maxwell sued Samsung for allegedly violating as many as seven patents and selling products that infringed upon them, including smartphones, laptops, and smart home appliances. It covers features such as device unlocking, information processing, networking, and the reproduction of images and videos. The report claims that Samsung and Maxwell had a working relationship dating back to 2011. In 2011, Samsung signed a licensing agreement with Maxwell’s predecessor, Hitachi, to use 10 of its patents for 10 years. However, that agreement ended in 2021, after which Samsung did not renew the license. Maxwell says it attempted to contact Samsung about renewing the license, but Samsung refused, claiming that those patents were invalid. This led to Maxwell taking the Korean tech giant to court. Maxwell has sued Samsung in several countries, including Germany, Japan, and the USA. We can’t speak to the legal outcome in those countries, but in the US, a court ruled that Samsung infringed on those patents and ordered Samsung to pay Maxwell damages of $117.7 million. Samsung can appeal the ruling if it isn’t satisfied, so we’ll have to wait and see. Another epic legal battle for the ages? This is not the first time Samsung has been involved in a lawsuit over alleged patent infringements. The company’s most notorious lawsuit involved Apple. The lawsuit between them went back and forth for many years, leading to injunctions, banned products, and more. The lawsuit was eventually settled, with neither side walking away unscathed. Patent lawsuits are pretty common in the tech industry. Some are legitimate claims. Others are filed by patent trolls, companies, or individuals who register vague patents in an attempt to force other companies to settle to avoid a lengthy lawsuit. The post Samsung Faces Big Penalty for Violating Key Unlocking Patents appeared first on Android Headlines.

    Intel Wins Jury Trial Over Patent Licenses In $3 Billion VLSI Fight

    A Texas jury ruled that Intel may hold a license to patents owned by VLSI Technology through its agreement with Finjan Inc., both controlled by Fortress Investment Group -- potentially nullifying over $3 billion in previous patent infringement verdicts against Intel. Reuters reports: VLSI has sued Intel in multiple U.S. courts for allegedly infringing several patents covering semiconductor technology. A jury in Waco, Texas awarded VLSI $2.18 billion in their first trial in 2021, which a U.S. appeals court has since overturned and sent back for new proceedings. An Austin, Texas jury determined that VLSI was entitled to nearly $949 million from Intel in a separate patent infringement trial in 2022. Intel has argued in that case that the verdicts should be thrown out based on a 2012 agreement that gave it a license to patents owned by Finjan and other companies "under common control" with it. U.S. District Judge Alan Albright held the latest jury trial in Austin to determine whether Finjan and VLSI were under the "common control" of Fortress. VLSI said it was not subject to the Finjan agreement, and that the company did not even exist until four years after it was signed. Read more of this story at Slashdot.

    TGIF: Maestro Trump and Drug Prices

    When encountering a public problem, people tend to fall into one of two camps: one camp, the larger one, says, "There oughta be a law." The other one asks, "How has the government created or aggravated the situation?" We know which camp Maestro Trump belongs to. Take prescription-drug prices. Because Americans pay higher prices on average for prescription drugs under patent (but not for generics) than people in other countries pay, Trump, who used to call price controls "socialist," has ordered the drug companies "to offer American consumers the most-favored-[developed-]nation lowest price." He wants private companies to lower their prices at home and raise them abroad. Is this a command? Trump's executive order goes on: "should drug manufacturers fail to offer American consumers the most-favored-nation lowest price, my Administration will take additional aggressive action." We know what that means. "If ... significant progress towards most-favored-nation pricing for American patients is not delivered," his order says, "to the extent consistent with law,... the Secretary [of health and human services] shall propose a rulemaking plan to impose most-favored-nation pricing." Got that? Impose. Why did Trump change his mind about price controls? Because now it fits with his demagogic populist politics of national grievance, which has served him so well. He vows to end "global freeloading" by foreigners who pay less. He believes that Americans subsidize foreigners. But do we? Good economics says otherwise. (We'll get to that.) The Maestro seems not to realize that price controls have failed for 4,000 years! They bring shortages, reduce innovation, and cause other distortions, which the government then tries to fix by expanding its restrictions. Never mind that the government makes drugs more expensive than they would be in an unhampered market. Prices will differ from country to country for sensible reasons. Economists call this market segmentation and price discrimination. Some people in certain circumstances are willing and able to pay more than others whose circumstances differ. We see this with airline fares and off-peak movie ticket prices. Americans are richer than other people and can afford to buy things that others couldn't and wouldn't buy at American prices. Sure, everyone prefers all prices to be lower—except his own, of course—but does that mean the government could mandate lower prices without negative consequences for all? No. Once a modern drug is produced and sold in the rich American market at a price high enough to yield a profit and recoup the stratospheric R&D costs, the drug maker can produce additional quantities at a low marginal cost and profitably expand sales to poorer people abroad at a lower price. This is good for the foreign buyers who otherwise wouldn't have access, but it does not harm Americans: regardless of what others pay, they buy the drug because they think the benefits exceed the cost. A government decree to make prices more equal would be harmful all around. As economist Alex Tabarrok writes, banning price discrimination "will end up hurting patients in low-income countries while delivering minimal gains to Americans. Worse, by reducing pharmaceutical profits overall, it weakens incentives to develop new drugs. In fact, in the long-run U.S. consumers are better off when poorer countries pay lower prices—just as airline price discrimination makes more routes viable for both economy and first-class passengers." Likewise, if movie theaters couldn't price-discriminate, we'd have fewer theaters and less service from surviving theaters because profitably filling seats at off-peak times would not be an option. When the government restricts profits, it restricts supply and innovation. That we lack a fully free market today does not substantially change the analysis. We can be confident that government intervention makes medical care artificially expensive by imposing artificial costs, restricting supply, and stimulating demand. A ban on global price discrimination would hardly help improve things. We'd have fewer new drugs. (Watch Alex Tabarrok and Robert Murphy discuss this and related issues.) This case against Trump's executive order is valid even when we acknowledge that foreign buyers of American drugs are governments that impose price controls. As many have pointed out, importing other countries' price controls makes no sense. No discussion of drug prices is complete without noting the burdens imposed by the Food and Drug Administration (FDA) and the patent system. Bringing a drug to market costs upward of $2 billion, and most never make it. Private competitive testing and certification firms (analogous to Consumer Reports) could replace the FDA and the prescription requirement. With informed consent, people should be free to take medicines that have undergone different degrees of testing. Life is risk. The government can't change that. Regarding the patent system, while 15-year monopoly pricing to some extent offsets the FDA burden, it should be abolished along with that agency. Because of vigorous competition, Americans pay far less for out-of-patent generic drugs than the rest of the world. Intellectual property is inconsistent with property rights because it prohibits manufacturers from using their own physical property to produce things. Unlike finite physical property, ideas aren't properly ownable: when an idea is communicated to others, the first person still retains it. Its economic value may fall, but no one has a property right in a thing's market value. For those who fear that the end of drug patents would spell the end of innovation, see Michele Boldrin and David K. Levine's Against Intellectual Property, which has a chapter on the international pharmaceutical industry. Trump's plan to tamper with drug prices will reduce profits to "Big Pharma"—ooh, what a scary term!—impede innovation, and make everyone less healthy in the future. Drugs currently under patent may seem expensive, but as Tabarrok points out, many modern drugs reduce the need for more costly and dangerous surgeries, and most drugs are paid for through insurance policies. (The government also makes insurance artificially expensive through mandated coverage and discriminatory tax treatment.) Moreover, as Tabarrok says, Americans get new drugs first. So, all things considered, drug prices don't look so bad after all. The moral and economic case for freeing the market is watertight, but that doesn't mean what we have now is worthless and could not become worse with more intervention.  America's interventionist medical system must be replaced by a free market in medicine. Most of every dollar spent on medical care today is paid for or mandated by the U.S. government. Barack Obama's Affordable Care Act made a flawed system worse. Coercion, which includes medical licensing, hospital certification, and official accreditation of medical schools, should be eliminated because nothing has proved better at delivering goods and services than the competitive profit-and-loss system directed at consumer satisfaction. Atom

    Patent Drawing for K. Lange’s Double Bicycle for Looping the Loop

    Patent Drawing for K. Lange’s Double Bicycle for Looping the Loop Record Group 241: Records of the Patent and Trademark OfficeSeries: Utility Patent Drawings 208. VELOCIPEDES. Frames 199.670 No. 790,063 Patented May 16, 1905. K. Lange. Double Bicycle for Looping the Loop. Application Filed Mar. 24, 1904 Fig. 1 [figure of a person sitting on a bicycle with a second bicycle testing upside down on the person’s back] Fig. 2 [illustration of the bicycle on a flat plane and on a curved surface where it goes upside down] Witnesses: F. A. Stewart C. E. Mureany Inventor: Karl Lange Edgar Tate & Co. BY Attorneys Passed Oct. 28-04 [left side] Double Bicycle for Looping the Loop Karl Lange Filed Mch 24 04 no. Model 063

    Using Trade Policy to Counter Anti-Suit Injunctions and Strengthen Global Patent Enforcement

    Patents are property rights that drive innovation, investment, and economic growth, which are especially critical in technology sectors that rely on global standards. Robust, enforceable patent protections have underpinned America’s technological leadership and economic prosperity by ensuring innovators are rewarded for their investments.  These property rights are, however, increasingly threatened by strategic judicial actions from abroad—in particular, the issuance of anti-suit injunctions (ASIs). ASIs are judicial orders that prohibit litigants from initiating or continuing patent-enforcement proceedings in another jurisdiction. They serve as a powerful procedural tool that can prevent parallel litigation in multiple forums simultaneously.  While ASIs traditionally help maintain judicial efficiency and avoid conflicting decisions, their recent application—especially in disputes over standard-essential patents (SEPs)—has evolved into a strategic battle to secure jurisdictional advantage. An emerging central issue concerns national courts that assert their authority to set FRAND (“fair, reasonable, and nondiscriminatory”) licensing rates globally, leading to heightened jurisdictional conflicts and creating a potential “race to the bottom” scenario in global patent enforcement. This strategic use of ASIs (notably, in jurisdictions like China) is often linked to broader industrial-policy objectives—i.e., controlling international licensing terms by effectively devaluing foreign-held patents. Such judicial tactics undermine the foundational principle of territoriality in patent law. They also threaten the stability of global intellectual-property regimes by compelling patent holders into accepting licensing terms dictated by the most assertive jurisdiction, which can result in artificially low royalty rates. Anti-Suit Injunctions in Global Patent Disputes  An anti-suit injunction (ASI) is a court order (typically, an interlocutory one) that restrains a party from initiating or continuing legal proceedings in other jurisdictions. This powerful judicial tool targets a specific litigant, rather than the foreign court itself, with the goal of avoiding conflicting judgments or parallel proceedings that could undermine the domestic court’s authority. For example, in a notable case between Samsung and Ericsson involving patents essential to 4G and 5G wireless standards, Samsung sought and obtained an ASI from a court in Wuhan, China, prohibiting Ericsson from pursuing patent-enforcement actions in the United States and other jurisdictions. In response, a U.S. court issued an anti-anti-suit injunction (AASI) that blocked Samsung’s Chinese order and allowed Ericsson’s U.S. litigation to continue. ASIs are commonly employed to protect a court’s jurisdiction, prevent redundant litigation, and enforce contractual agreements—such as exclusive jurisdiction or arbitration agreements. In that context, they seek to promote judicial efficiency and uphold the principle of contractual freedom. But the ASI landscape has shifted dramatically, as they are increasingly invoked in complex, multi-jurisdictional disputes over SEPs subject to FRAND licensing terms. This surge has seen courts in various countries (most notably China) actively use ASIs as strategic weapons in high-stakes battles involving major technology companies.   This aggressive use of ASIs has triggered a jurisdictional “ping-pong game,” with courts in targeted nations responding with their own AASIs to neutralize the initial ASI and to protect their own jurisdiction. For instance, in a dispute between InterDigital and Xiaomi, after Xiaomi obtained an ASI from a Wuhan court preventing InterDigital from pursuing patent enforcement in India, the Delhi High Court issued an AASI that allowed InterDigital to proceed with its infringement actions in India—thus directly countering the Chinese court’s ASI and reinforcing India’s jurisdiction over the case.  We’ve seen such AASIs emerge from courts in the United States, India, and Europe—including the Unified Patent Court (UPC), which has shown a willingness to issue AASIs to defend its nascent jurisdiction. This escalation, which has sometimes even led to “anti-anti-anti-suit injunctions” (AAASIs), signals intensifying conflicts and a potential breakdown of international comity. Recent developments continue to shape this evolving field. The U.S. Court of Appeals for the Federal Circuit’s October 2024 decision in Ericsson v. Lenovo clarified the “dispositive” requirement for an ASI, potentially making them somewhat easier to obtain in U.S. SEP cases by holding that an ASI can be justified even if it only resolves a foreign injunction, rather than the entire foreign proceeding. Meanwhile, the EU’s World Trade Organization (WTO) dispute against China’s ASI practices saw a panel rule in early 2025 that, while China failed on certain transparency obligations, its ASI policies were not inconsistent with the Agreement on Trade-Related Aspects of Intellectual Property Rights (“TRIPS Agreement”). This decision has been appealed by both the EU and China, with an outcome expected in the latter half of 2025. ASIs as Industrial Policy The strategic deployment of ASIs by foreign courts—particularly those in managed economies like China—can function to effectively expropriate the value of patent rights from their U.S. owners. This aggressive use is not merely procedural; it aligns with broader industrial-policy objectives aimed at shifting the global technological balance, often by transitioning a nation from a net licensee to a net licensor of technology. Chinese courts have notably used ASIs in cases involving domestic technology leaders like Huawei and Xiaomi, shielding these companies from litigation abroad, while consolidating global disputes in China. These actions can be seen as strategic steps to assert China’s growing role as a global technology licensor.  Indeed, the significant economic and national interests intertwined with FRAND disputes often lead courts to adopt stances that favor domestic companies or strategic national goals. This calculated approach, where ASIs become instruments of economic statecraft, harms U.S. innovators. ASIs directly obstruct U.S. patent holders from enforcing their legitimate property rights in their chosen forums, which might include U.S. courts or other jurisdictions perceived as more favorable for upholding patent validity and ensuring fair compensation. In the Ericsson v. Samsung dispute, Samsung’s ASI from a Wuhan court was specifically designed to consolidate the global licensing dispute in China, ensuring exclusive authority over the terms. The European Union has voiced similar concerns, noting that Chinese ASIs can compel patent holders to accept lower-than-market royalty rates under duress. This artificially diminishes the patent holder’s leverage in negotiations, effectively devaluing their patent portfolio and coercing them into unfavorable licensing terms globally. When foreign courts combine issuing ASIs with assertions that they have jurisdiction to set FRAND royalty rates global, it can instigate a “race to the bottom” in which litigants shop for jurisdictions most likely to impose the lowest rates. This threatens to distort global licensing markets and undermine efficient, market-based outcomes. The proliferation of conflicting injunctions also generates enormous transaction costs (ultimately passed on to consumers), as resources are diverted from innovation to “meta-litigation” over jurisdictional supremacy.  This environment of heightened legal uncertainty and escalating litigation expenses discourages R&D investment in the United States, as the ability to reliably enforce IP rights globally is compromised. Moreover, the strategic use of ASIs to frustrate U.S. patent rights represents a profound disrespect for the sovereignty of U.S. courts and the territorial nature of patents. It generates international friction and disrupts the comity that should govern international legal relations. Arguments justifying ASIs often cite their utility in promoting judicial efficiency, preventing duplicative or vexatious parallel litigation, and upholding the authority of domestic courts, particularly in enforcing arbitration agreements or countering forum shopping. Some scholars suggest the current “ping-pong game” of global ASIs stems not just from procedural tactics, but from such deeper issues as significant national economic interests in SEPs, a regulatory void in FRAND dispute resolution, and divergent national choice-of-law rules. It’s also posited that China’s assertive use of ASIs and its global rate-setting ambitions could be a defensive reaction to similar extraterritorial reach by Western courts (notably in the UK) or a legitimate move to protect its own judicial sovereignty and reflect its growing stature as a technology licensor, rather than just a licensee. But while ASIs are not unique to China, and systemic issues do contribute to jurisdictional friction, Chinese ASIs are distinguished by their sweeping global scope, frequent ex-parte issuance, opaque judicial processes, and clear alignment with a national industrial policy that seeks to suppress global royalty rates.  Such strategically deployed ASIs appear designed to devalue foreign-held patents and dictate global terms under a preferred national framework. This suggests that, to at least some degree, the use of ASIs can constitute protectionist behavior that distorts efficient market outcomes and fundamentally undermines property rights, rather than fostering genuine comity or legitimate judicial management. A Trade-Policy Toolkit to Protect US Innovation  While recent attention has understandably focused on China’s rapid and expansive deployment of ASIs, it is important to recognize that the strategic use of such injunctions did not originate there. Courts in the United States and the United Kingdom, among others, have also issued ASIs in significant SEP cases, sometimes setting precedents that other jurisdictions (including China) have subsequently adopted and expanded.  There are also legitimate procedural reasons to employ ASIs, such as preventing duplicative litigation, enforcing arbitration agreements, or protecting jurisdictional integrity. The key concern arises when their deployment evolves beyond these legitimate purposes and becomes a strategic tool closely aligned with national industrial-policy objectives. Thus, addressing these jurisdictional tensions effectively will require nuanced international cooperation and reforms that extend beyond any single nation’s practices. Addressing the strategic misuse of ASIs and the consequent devaluation of U.S. intellectual property requires a comprehensive strategy that extends beyond reactive, case-by-case litigation. The most effective path forward for the United States would be to leverage existing trade-policy tools to address the issue. For example, the Office of the U.S. Trade Representative (USTR) could continue to prominently feature concerns about the misuse of ASIs (especially those emanating from China) in its annual Special 301 Report, potentially elevating countries that engage in such practices to the “Priority Watch List” to maintain pressure on them and underscore the seriousness of the issue. It could also seek to include provisions in new and existing bilateral and multilateral trade agreements that explicitly discourage or prohibit the use of ASIs that unduly interfere with the legitimate enforcement of patent rights in other jurisdictions. In the multilateral arena, the United States might more vigorously support efforts at the WTO to challenge practices that undermine TRIPS obligations. This includes continuing to highlight the economic harm and trade distortions caused by strategically deployed ASIs, even if initial panel rulings, like those in the EU-China dispute (DS611), are unfavorable on certain interpretations of TRIPS.  Furthermore, domestic legislative solutions warrant serious consideration. Congress should re-evaluate and consider enacting measures similar to the Defending American Courts Act (DACA). Such legislation could create significant disincentives for parties attempting to enforce foreign ASIs that undermine U.S. court proceedings or International Trade Commission investigations—e.g., by imposing presumptions of willful infringement or by limiting their ability to challenge patents at the U.S. Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board. The overarching goal of these concerted actions should be to ensure a global playing field in which innovation is rewarded through strong and enforceable intellectual-property rights. The strategic international deployment of ASIs, particularly when used to diminish the value of American intellectual property by dictating global licensing terms, poses a direct threat to the property rights that underpin much U.S. innovation and economic competitiveness. To safeguard the interests of American innovators and maintain technological leadership, the United States should employ a robust and assertive trade policy, coupled with domestic reforms, that can counter these jurisdictional challenges and ensure that patent rights are upheld worldwide. The post Using Trade Policy to Counter Anti-Suit Injunctions and Strengthen Global Patent Enforcement appeared first on Truth on the Market.

    Another Director Review Request Demonstrates Extent of PTAB Hubris

    Last week, yet another request for Director Review shined a light on what has become the seedy underbelly of the Patent Trial and Appeal Board (PTAB). In Innoscience Technology Co. LTD., v. Efficient Power Conversion Corp. (IPR2023-01381), not only did the PTAB institute a challenge brought by a China-based infringer (Innoscience) against a U.S.-based patent owner (Efficient Power Conversion), but the challenge was instituted after completion of a week-long trial at the International Trade Commission (ITC) and during the process of post-trial briefing.

    Medical Devices: obtaining Patent Protection in Brazil

    ANVISA (the Brazilian regulatory authority) is considering updating rules addressing medical devices in a clear indication that this market is growing and requires more attention. Medical devices play a vital role in healthcare, having evolved from simple tools like thermometers and bandages to sophisticated technologies such as robotic surgical systems, implantable neurostimulators, and AI-powered diagnostics. Recent innovations, driven by progress in electronics, materials science, biotechnology, and information technology, have led to a new generation of devices that integrate hardware, software, data analytics, and connectivity. These include wearable monitors with ECG capabilities, mobile health applications, implantable devices, and software-based diagnostics. The rise of Software as a Medical Device (SaMD) and the Internet of Medical Things (IoMT) has further expanded the definition of medical devices, enabling real-time monitoring, remote diagnostics, and personalized treatment. As this interdisciplinary field continues to evolve, securing patent protection becomes a strategic necessity to ensure market exclusivity and to attract investment. Patentability of Medical Devices in Brazil Article 10 of the Brazilian Industrial Property Statute (Law No. 9,279/96) outlines what isn’t considered patent-eligible subject matter, with item VIII excluding diagnostic, therapeutic, and surgical methods practiced on the human or animal body, and item V excluding software per se. Despite these restrictions, medical devices are frequently eligible for patent protection when claims emphasize their technical features. Devices with well-defined physical structures, integrated hardware-software systems, and novel configurations that produce a technical effect are generally considered patentable. Even inventions involving diagnostic or therapeutic use may be protected if claims are directed to the device or a technical process rather than the medical act itself. For example, a diagnostic system that processes imaging data may be patentable if claims focus on the image processing functionality rather than the diagnostic step. Enablement and Written Description Requirements To meet the enablement requirement, patent applications must provide sufficient technical details to allow a person skilled in the art to reproduce the invention. For medical devices, this includes, for instance, descriptions of structural components such as sensors, processors, and actuators, as well as diagrams illustrating the device’s operation. For inventions involving software, particularly AI or machine learning models, the application should explain how the software interacts with the hardware, how the system processes inputs, and what outputs it generates. For AI-powered systems, disclosing information about training datasets and inference models may be necessary to demonstrate technical contribution and sufficiency of disclosure. The Brazilian PTO places significant emphasis on claim clarity. Vague or purely functional language, such as “configured to” or “adapted for,” must be supported by concrete examples and detailed descriptions in the specification. This ensures that the invention is both clearly understood and enforceable. Examples of BRPTO’s Examination of Medical Device Applications Several cases decided by the BRPTO demonstrate how medical device patent applications can overcome objections and secure protection: UFMG (PI0902539-1): This application claimed a device and method for identifying cardiac arrhythmias and electrolyte abnormalities via ECG signal analysis. It was initially rejected under Article 10(VIII) of the Brazilian IP Statute for being a diagnostic method applied to the human body. However, on appeal, the applicant clarified that the signals are received, saved and processed offline, meaning the signal processing to detect arrhythmias and measure heart rate variability occurred independently of direct application to a patient. The second-instance examiners then reversed the rejection decision, citing Rule #411/16, which allows diagnostic methods that are not applied directly to the body to be considered inventions, even when implemented via computer. Another example of acceptable subject matter provided by the rule is electrocardiographic signal processing methods used to generate parameters that assist a physician in diagnosing pathologies. INTERMED (PI0705091-7): This application is related to a hospital-grade ventilator system intended to monitor and mechanically control pulmonary ventilation. The system includes physical components such as valves, tubes, connectors, sensors, solenoids, microprocessors, and control units. Initially rejected under Article 10(VIII), but, on appeal, the second-instance examiners recognized that the invention is a medical apparatus comprising several components which together perform a technical method, and not a method practiced on the human body. This case demonstrates how well-defined physical structures, and clear technical contributions can overcome objections under Article 10. SUN PHARMACEUTICAL INDUSTRIES (BR112018016287-6): The application relates to a perfusion system comprising a plurality of containers pre-filled with aqueous solutions of antineoplastic drugs at predefined concentrations. The system included instructions for combining these containers to prepare a patient-specific dose within an acceptable deviation margin, without manipulating the drug solutions. The BRPTO initially rejected this application as being a therapeutic method. On appeal, the patent office concluded that the claims defined a product, not a therapeutic act. The case was then returned to the first instance for further examination of patentability requirements. This case is noteworthy for illustrating how product-focused claims—especially those involving drug delivery systems—can avoid exclusion under Article 10 (VIII) if they are carefully drafted to emphasize structure and functionality over therapeutic purpose. IMPLANTICA PATENT (BR122019021070-5): This divisional application, derived from PI0906747-7, claimed an implantable device for treating obesity, featuring adjustable expansion mechanisms, surface textures to prevent fibrosis, fluid volume control systems, and optional patient monitoring sensors. The application was initially rejected on the grounds of double patenting, as well as lack of clarity and enablement. On appeal, the BRPTO determined that the specification met formal requirements and that there was no overlap with the original application. The second-instance examiner concluded that, although both applications shared a common inventive concept, they were based on distinct technical features: the original application covered a device positioned externally in the stomach via a non-invasive approach, while the divisional claimed a device intended for internal attachment within the stomach. Synthes GMBH (PI 0815225-0): The application is related to a system for attaching a bone plate to bone tissue, and a method for forming holes in the plate. The claims were initially rejected for lack of novelty. However, the second-instance examiners identified meaningful distinctions from the prior art and proceeded directly to a new substantive examination, ultimately granting the patent. Conclusion and Strategic Recommendations Obtaining patent protection for medical devices in Brazil requires familiarity with local legal provisions and BRPTO examination practices. Applications should: Avoid claiming subject matter excluded under Article 10 by emphasizing the technical characteristics of the invention. Ensure software- and diagnostics-related inventions are tied to physical components or to steps of the methods/processes that clearly demonstrate a technical effect. Provide detailed, reproducible descriptions to satisfy enablement and clarity requirements. Anticipate possible objections and proactively address them during the drafting process. More from our authors: Vissers Annotated European Patent Convention 2024 Edition by Kaisa Suominen, Nina Ferara, Peter de Lange, Andrew Rudge € 105 Annotated PCT by Malte Köllner € 160 AI Governance and Liability in Europe: A Primer by Ceyhun Necati Pehlivan, Nikolaus Forgó, Peggy Valcke € 150

    Ingenico and the Federal Circuit’s Elimination of IPR Estoppel

    Recent U.S. Court of Appeals for the Federal Circuit decisions have gutted 35 U.S.C. §315(e)(2). Last week, in Ingenico Inc. v. IOENGINE, LLC, 2025 WL 1318188 (Fed. Cir. 2025), the Federal Circuit resolved an open issue regarding IPR estoppel in district court, holding that system art is never subject to IPR estoppel under 35 U.S.C. §315(e)(2). But Ingenico went much further and also held that “IPR estoppel does not preclude a petitioner from relying on the same patents and printed publications as evidence in asserting a ground that could not be raised during the IPR, such as that the claimed invention was known or used by others, on sale, or in public use.”

Add a blog to Bloglovin’
Enter the full blog address (e.g. https://www.fashionsquad.com)
We're working on your request. This will take just a minute...